GSK plc GSK-GB:London Stock Exchange

RT Quote | Exchange | GBp

Last | 4:45 PM GMT

1,501.00

+15.40 (+1.04%)

52 week range

1,280.92 - 1,842.76

Open1,495.80
Day High1,513.20
Day Low1,489.80
Prev Close1,485.60
52 Week High1,842.76
52 Week High Date07/06/22
52 Week Low1,280.92
52 Week Low Date09/22/22

Key Stats

Market Cap71,060.51M
Shares Out4,067.38M
10 Day Average Volume12.87M
Dividend90.00
Dividend Yield6.00%
Beta0.42
YTD % Change4.41

KEY STATS

Open1,495.80
Day High1,513.20
Day Low1,489.80
Prev Close1,485.60
52 Week High1,842.76
52 Week High Date07/06/22
52 Week Low1,280.92
52 Week Low Date09/22/22
Market Cap71,060.51M
Shares Out4,067.38M
10 Day Average Volume12.87M
Dividend90.00
Dividend Yield6.00%
Beta0.42
YTD % Change4.41

RATIOS/PROFITABILITY

EPS (TTM)117.98
P/E (TTM)12.72
Fwd P/E (NTM)-
EBITDA (TTM)-
ROE (TTM)-
Revenue (TTM)-
Gross Margin (TTM)-
Net Margin (TTM)-
Debt To Equity (MRQ)-

EVENTS

Earnings Date-
Ex Div Date02/23/2023
Div Amount13.75
Split Date-
Split Factor-

Latest On GSK plc

Pro Picks: Watch all of Monday's big stock calls on CNBCFebruary 6, 2023CNBC.com
Investor Sarat Sethi said he is buying into this 'unloved' pharma stockFebruary 6, 2023CNBC.com
RSV vaccine: Moderna, Pfizer start a new FDA approval raceJanuary 18, 2023CNBC.com
Cramer's lightning round: I think Boeing is goodJanuary 17, 2023CNBC.com

Content From Our Affiliates

GSK, Cytel enter three-year agreement to expand Solara deploymentFebruary 7, 2023TipRanks
GSK price target raised to 1,400 GBp from 1,350 GBp at JPMorganFebruary 2, 2023TipRanks
Akebia should update on vadadustat FDA process in next month, says Piper SandlerFebruary 2, 2023TipRanks
GSK reports Jesduvroq approved by FDA for anemia of CKD in adults on dialysisFebruary 2, 2023TipRanks
Ionis Pharmaceuticals: GSK advances bepirovirsen into Phase 3 developmentFebruary 1, 2023TipRanks

Profile

GSK plc is a global biopharma company. The Company makes vaccines and specialty medicines to prevent and treat disease. Its segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed a new monoclonal antibody treatment for COVID-19. Its product areas include vaccines, specialty medicines, and general medicines. Its vaccine portfolio...

Jonathan Symonds CBE

Independent Non-Executive Chairman of the Board

Emma Walmsley

Chief Executive Officer, Executive Director

Iain Mackay

Chief Financial Officer, Executive Director

Address

980 Great West Road

Brentford

TW8 9GS

United Kingdom

https://www.gsk.com/